Academic Journal
Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma
| العنوان: | Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma |
|---|---|
| المؤلفون: | Changlin Yang, Vrunda Trivedi, Kyle Dyson, Tongjun Gu, Kate M. Candelario, Oleg Yegorov, Duane A. Mitchell |
| المصدر: | Genome Medicine, Vol 16, Iss 1, Pp 1-19 (2024) |
| بيانات النشر: | BMC, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medicine LCC:Genetics |
| مصطلحات موضوعية: | Neoantigens, Tumor-associated antigens (TAAs), Medulloblastoma, Antigen landscape, Immunogenomics, Medicine, Genetics, QH426-470 |
| الوصف: | Abstract Background The current standard of care treatments for medulloblastoma are insufficient as these do not take tumor heterogeneity into account. Newer, safer, patient-specific treatment approaches are required to treat high-risk medulloblastoma patients who are not cured by the standard therapies. Immunotherapy is a promising treatment modality that could be key to improving survival and avoiding morbidity. For an effective immune response, appropriate tumor antigens must be targeted. While medulloblastoma patients with subgroup-specific genetic substitutions have been previously reported, the immunogenicity of these genetic alterations remains unknown. The aim of this study is to identify potential tumor rejection antigens for the development of antigen-directed cellular therapies for medulloblastoma. Methods We developed a cancer immunogenomics pipeline and performed a comprehensive analysis of medulloblastoma subgroup-specific transcription profiles (n = 170, 18 WNT, 46 SHH, 41 Group 3, and 65 Group 4 patient tumors) available through International Cancer Genome Consortium (ICGC) and European Genome-Phenome Archive (EGA). We performed in silico antigen prediction across a broad array of antigen classes including neoantigens, tumor-associated antigens (TAAs), and fusion proteins. Furthermore, we evaluated the antigen processing and presentation pathway in tumor cells and the immune infiltrating cell landscape using the latest computational deconvolution methods. Results Medulloblastoma patients were found to express multiple private and shared immunogenic antigens. The proportion of predicted TAAs was higher than neoantigens and gene fusions for all molecular subgroups, except for sonic hedgehog (SHH), which had a higher neoantigen burden. Importantly, cancer-testis antigens, as well as previously unappreciated neurodevelopmental antigens, were found to be expressed by most patients across all medulloblastoma subgroups. Despite being immunologically cold, medulloblastoma subgroups were found to have distinct immune cell gene signatures. Conclusions Using a custom antigen prediction pipeline, we identified potential tumor rejection antigens with important implications for the development of immunotherapy for medulloblastoma. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1756-994X |
| Relation: | https://doaj.org/toc/1756-994X |
| DOI: | 10.1186/s13073-024-01363-y |
| URL الوصول: | https://doaj.org/article/8684278dd84441a8814e938fc4589449 |
| رقم الانضمام: | edsdoj.8684278dd84441a8814e938fc4589449 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 1756994X |
|---|---|
| DOI: | 10.1186/s13073-024-01363-y |